Geron, Exeter Affiliates Merge to Create Livestock Cloning Shop
By GenomeWeb,
GenomeWeb
| 08. 12. 2008
NEW YORK (GenomeWeb News) - Geron and Exeter Life Sciences said today that Start Licensing, a joint venture between the two firms, and ViaGen, a subsidiary of Exeter, have merged to form a new entity that will focus on animal cloning.
Start manages and licenses a portfolio of intellectual property rights related to animal reproductive technologies, including nuclear transfer cloning technology that was developed at the Roslin Foundation to clone Dolly the sheep. ViaGen is an animal genomics and livestock cloning firm.
Geron and Exeter said that the merger of the firms combines the "full breadth" of Start's nuclear transfer cloning IP with ViaGen's in-house breeding services and expertise in advanced reproductive technologies, including cloning, "to provide a one-stop licensing and operating company" for animal cloning.
"We believe it makes sound business sense to join a patent estate for nuclear transfer that has been tested and is recognized as dominant with a leading operating company in the field," said David Greenwood, Geron's executive vice president and CFO, in a statement.
Jonathan Thatcher, Exeter Life Science's CEO, said that the combined...
Related Articles
By Rhys Blakely, The Times | 06.24.2025
Scientists have created fertile mice from male genetic material alone, a breakthrough that could one day open the door to human babies who inherit their genes from two fathers.
The experiment, led by Professor Yanchang Wei at Shanghai Jiao Tong...
By Ron Leuty, San Francisco Business Times | 06.16.2025
23andMe's two-step sale to a nonprofit led by former CEO Anne Wojcicki is nothing more than a dance around California's genetic privacy law, state Attorney General Rob Bonta said in a filing late Monday, one day before a judge will...
By Angus Liu, Fierce Pharma | 06.16.2025
A second patient has died following treatment with Sarepta Therapeutics’ Elevidys, raising more doubts about the Duchenne muscular dystrophy (DMD) gene therapy’s safety profile.
Sarepta and its ex-U.S. partner Roche reported the death early Sunday. Like the first case, disclosed...
By Gina Kolata, The New York Times | 06.20.2025
A single infusion of a stem cell-based treatment may have cured 10 out of 12 people with the most severe form of type 1 diabetes. One year later, these 10 patients no longer need insulin. The other two patients need...
